Sharekhan's research report on Cipla
Profitability strongly beat ours and consensus estimates in Q1FY2024 by 15.7% and 15.9%, respectively, driven by continued strong growth in the US and a recovery in India, leading to an improved products mix. US business growth was driven by continued performance of key products such as gRevlimid and Lanreotide and stability in market share of Albuterol. A rise in chronic segment’s revenues aided a recovery in India business’ revenues.
Outlook
We revise our earnings growth estimate to 22.6% over FY23-FY25E from a 15.2% CAGR earlier, and hence upgrade the PT to Rs. 1279 (vs. before Rs. 1,030) and also upgrade the rating to Buy. Stock trades at a lower level of ~22.7x and ~19.4x its FY24 and FY25E EPS estimates vs. peers trading at ~28.2x and ~23.3x its FY24E and FY25E EPS estimates, indicating attractive valuation.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.